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ABSTRACT 
  Bovine parainfluenza virus type 3 (BPIV3) is an important pathogen associated with 
bovine respiratory disease complex (BRDC). We have generated a recombinant BPIV3 
expressing enhanced green fluorescent protein (rBPIV3-EGFP) based on the BN-1 
strain isolated in Japan. After intranasal infection of hamsters with rBPIV3-EGFP, 
EGFP fluorescence was detected in the upper respiratory tract including the nasal 
turbinates, pharynx, larynx, and trachea. In the nasal turbinates, rBPIV3-EGFP attained 
high titers (> 106 TCID50/g of tissue) 2 to 4 days after infection. Ciliated epithelial 
cells in the nasal turbinates and trachea were infected with rBPIV3-EGFP. 
Histopathological analysis indicated that mucosal epithelial cells in bronchi were shed 
by 6 days after infection, leaving non-ciliated cells, which may have increased 
susceptibility to bacterial infection leading to the development of BRDC. These data 
indicate that rBPIV3-EGFP infection of hamsters is a useful small animal model for 
studying the development of BPIV3-associated BRDC. 
 
INTRODUCTION 
    Bovine parainfluenza virus type 3 (BPIV3), a member of the genus Respirovirus 
in the family Paramyxoviridae, is an enveloped virus with a non-segmented 
negative-sense RNA genome (Karron and Collins, 2013). BPIV3 is one of the most 
important viruses associated with bovine respiratory disease complex (BRDC), 
commonly referred as “Shipping fever”, in cattle (Autio et al., 2007; Snowder et al., 
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 2007). The BPIV3 genome encodes six structural proteins: the nucleocapsid (N), 
phosphoprotein (P), matrix (M), fusion (F), hemagglutinin-neuraminidase (HN), and 
large (L) proteins. The P gene also encodes three accessory proteins, the C, V and D 
proteins. The C protein is translated from an alternative translation initiation site 
resulting in a different reading frame, and the V and D proteins are translated from 
edited mRNAs. Two envelope glycoproteins, the HN and F proteins, mediate receptor 
binding and membrane fusion, respectively. Therefore, the HN protein is primarily 
responsible for determining the tropism of BPIV3 (Karron and Collins, 2013). 
  The HN protein recognizes sialic acid-containing cellular glycoconjugates.  
Although the fine structure of sialic-acid residues that bind the HN protein of BPIV3 
have not yet been reported, those that bind to the HN protein of the closely related 
human parainfluenza type 3 virus (HPIV3) have been reported (Amonsen et al., 2007; 
Fukushima et al, 2014; Suzuki et al., 2001; Zhang et al., 2005). In a cell-based assay 
using an in vitro model of human airway epithelium and neuraminidases specific for 
α2-6-linked or α2-3-/α2-8-linked sialic acid residues, HPIV3 was reported to utilize 
α2-6-linked sialic acid residues for initiating infection (Zhang et al., 2005). On the 
other hand, in a non-cell-based assay using purified gangliosides, HPIV3 was reported 
to bind to both α2-3- and α2-6-linked sialic acid residues (Fukushima et al, 2014; 
Suzuki et al., 2001). In another non-cell-based assay using the glycan array of the 
Consortium for Functional Glycomics, HPIV3 was reported to bind α2-3-linked sialic 
acid residues (Amonsen et al., 2007). In addition, another study reported that HPIV3 
also utilized heparin sulfate moieties on the cell surface (Bose and Banerjee, 2002). 
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 Thus, the receptor specificity of HPIV3 and BPIV3 is still controversial. 
  For the pathogenesis of BPIV3, only limited studies of its pathogenesis in calves 
have been reported (Tsai and Thomson, 1975; Van der Maaten, 1969b). This virus also 
infects rhesus monkeys, chimpanzees, and humans, although replication is limited and 
restricted to the respiratory tract in those hosts (Karron and Collins, 2013). Hamsters 
are often used as small models for studying BPIV3 tropism (Van der Maaten, 1969a) 
and for evaluating the efficacy of recombinant BPIV3 vaccines (Haller et al., 2000; 
Schmidt et al., 2001). BPIV3 replicates in the respiratory tracts, but the systemic 
infection and the exact cell tropism of BPIV3 in hamsters have not yet been reported.     
  EGFP-expressing reporter viruses have been successfully used to study the cell 
tropism and pathogenesis of paramyxoviruses with high sensitivity (de Swart et al., 
2007; Takeuchi et al., 2012; von Messling et al., 2004). In our study, we examined the 
tropism and pathogenesis of BPIV3 in hamsters using the enhanced green fluorescent 
protein (EGFP)-expressing BPIV3 (rBPIV3-EGFP). We found that rBPIV3-EGFP 
efficiently replicated in the nasal turbinates, pharynx, larynx, and trachea of hamsters. 
Ciliated epithelial cells in the nasal turbinates and trachea were infected. In addition, 
rBPIV3-EGFP caused mucosal epithelial cell shedding in the bronchi. These data are 
important for understanding the pathogenesis of BPIV3 and BPIV3-associated BRDC.    
 
RESULTS 
Construction of the full-length BPIV3 cDNA and rescue of rBPIV3 and 
rBPIV3-EGFP. 
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   An infectious full-length antigenomic cDNA of BPIV3-BN-1 strain was constructed 
by RT-PCR amplification of genomic RNA to produce three DNA segments, which 
were assembled in sequential cloning step, resulting in the p(+)BPIV3 (Fig. 1).  As a 
genetic marker, an NheI restriction enzyme site in the HN gene was introduced in place 
of a StuI site. Recombinant BPIV3 (rBPIV3) was recovered from the p(+)BPIV3 (Fig. 
1).  To confirm that recovered virus was rBPIV3, PCR fragments of the HN gene of 
rBPIV3 and BPIV3 were analyzed for the presence of the NheI restriction enzyme site 
(Fig. 2). The 1020 bp PCR fragments derived from rBPIV3 was cleaved with NheI but 
not with StuI. In contrast, the PCR fragment derived from BPIV3 was cleaved with 
StuI but not with NheI as expected. Identification of NheI site demonstrated that 
recovered rBPIV3 was indeed derived from plasmid DNA containing the full-length 
rBPIV3 genome by reverse genetics.   
  To make recombinant BPIV3 expressing the EGFP, we introduced the EGFP gene 
between the N and P genes of the p(+)BPIV3, resulting in the p(+)BPIV3-EGFP. Then, 
infectious virus (rBPIV3-EGFP) was recovered from the p(+)BPIV3-EGFP. Repeated 
attempts to recover recombinant virus having the EGFP gene between the leader 
sequence and the N gene were not successful (data not shown). 
 
In vitro characterization of rBPIV3 and rBPIV3-EGFP. 
  First, we compared the growth of BPIV3, rBPIV3 and rBPIV3-EGFP in MDBK 
cells (Fig. 3A). All virus strains showed similar replication kinetics and attained peak 
titers of 1010 50% tissue culture infective dose (TCID50)/ml, suggesting that rBPIV3 
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 retained the phenotype of BPIV3 and that the EGFP gene had no obvious detrimental 
effect on the growth of rBPIV3-EGFP. rBPIV3-EGFP replicated and expressed EGFP 
in several other cell lines including CV-1, Vero, HeLa, HEp-2 and 293 cells, but did 
not induce syncytium formation (Fig. 3B).  
 
Macroscopic detection of EGFP fluorescence in organs and tissues. 
  To examine the systemic infection of BPIV3 in hamsters, we infected hamsters with 
rBPIV3-EGFP. Hamsters were infected intranasally with 1 × 106 TCID50 of 
rBPIV3-EGFP in a 100 µl volume. No clinical signs were observed during the course 
of the experiment. Upon necropsy at 2 days post-infection, EGFP fluorescence was 
detected in the nasal turbinates and weakly in the trachea of all hamsters. On day 4, 
strong EGFP fluorescence was detected in the entire region of the nasal turbinates, 
pharynx, larynx, and trachea of all hamsters (Fig. 4). There was no expression in other 
tissues and organs. EGFP-expressing cells were restricted in the lumen of the trachea 
(Fig. 4). Unexpectedly, EGFP fluorescence was not detected in any sections of the 
lungs of all hamsters. By day 6, the intensity of the EGFP fluorescence had rapidly 
weakened in those tissues and was no longer detectable by day 8.     
 
Growth of rBPIV3-EGFP in nasal turbinates and trachea of hamsters. 
  We then examined the growth of rBPIV3-EGFP in the nasal turbinates and trachea 
of infected hamsters. In the nasal turbinates, rBPIV3-EGFP attained very high titers (> 
106 TCID50/g of tissue) on days 2 and 4 post-infection (Table 1). A gradual reduction 
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 by 1 log10 was detected by day 6, and titers rapidly dropped by 3 log10 by day 8 (Table 
1). In the trachea, rBPIV3-EGFP attained high titers (104.5 TCID50/g of tissue) by day 2 
and increased to very high titers (105.7 TCID50/g of tissue) by day 4. Titers then 
decreased by 2 log10 by day 6 and were further reduced by 1 log10 by day 8, indicating 
that the infection was rapidly cleared within a few days.  
  We could not detect efficient virus growth in the lung (Table 1), although previous 
reports indicated efficient virus growth in both the nasal turbinates and lungs (Haller et 
al., 2000; Schmidt et al., 2001). To examine whether the EGFP gene introduced in 
rBPIV3-EGFP attenuated virus growth in lungs, we infected hamsters with 
recombinant virus without the EGFP (rBPIV3).  Again, rBPIV3 replicated efficiently 
in both the nasal turbinates (106.2 TCID50/g of tissue) and trachea (105.0 TCID50/g of 
tissue) but less efficiently in the lungs (103.7 TCID50/g of tissue) (Table 2), suggesting 
that the EGFP gene did not attenuate virus growth in the lungs of hamsters.  
  To examine whether lower numbers of virus can establish infection in hamsters, we 
infected hamsters with lower doses (105 or 104 TCID50 of virus per animal) of 
rBPIV3-EGFP.  When hamsters were infected with 105 or 104 TCID50 of 
rBPIV3-EGFP, 106.1 or 105.5 TCID50/g of tissue of virus were recovered from the 
trachea of hamsters, respectively (Table 2), indicating that lower doses of virus could 
still establish the infection in hamsters. 
 
Ciliated epithelial cells were preferentially infected with rBPIV3-EGFP. 
  To identify the infected cells in the nasal turbinates and tracheas, we observed frozen 
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 section of these tissues under a fluorescent microscope. Ciliated cells stained with 
cilia-specific antibody (β-tubulin IV) were found to be exclusively infected by 
rBPIV3-EGFP in both the nasal turbinates and trachea (Fig. 5A and B). Infection did 
not spread to underlying basal cells and did not induce syncytium formation between 
infected and uninfected cells. 
 
Mucosal epithelial cell shedding and lymphocytic infiltration. 
  To examine the pathogenesis of BPIV3 in hamsters, we performed a 
histopathological analysis of fixed specimens of the nasal turbinates, trachea, and 
bronchi. On day 6, sloughed ciliated epithelial cells, cell debris, and red blood cells 
were observed in the lumen of the bronchi (Fig. 6). Diffuse expansions of the alveolar 
interstitia due to mononuclear cell infiltrates were also observed on day 6, but not 
observed in on days 2 or 4.  Mucosal epithelial cells shed by day 6 post-infection left 
non-ciliated cells in the lumen of bronchi (Fig. 6).  
 
DISCUSSION AND CONCLUSIONS 
  In this study, we have analyzed the in vivo tropism of BPIV3 in hamsters using 
EGFP-expressing recombinant BPIV3 based on the BN-1 strain. Previous studies 
indicated that BPIV3 replicates in the respiratory tracts of hamsters (Haller et al., 2000; 
Schmidt et al., 2001; Van der Maaten, 1969a), but the systemic infection and the exact 
cell tropism of BPIV3 were not examined. We observed EGFP expression in the entire 
region of the nasal turbinates, pharynx, larynx, and trachea (Fig. 3). In particular, we 
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 detected high titers of virus (> 106 TCID50/g of tissues) on days 2 and 4 post-infection 
in the nasal turbinates (Table 1). These titers were equivalent or 10 times higher than 
those reported previously (Haller et al., 2000; Schmidt et al., 2001). Interestingly, 
rBPIV3-EGFP did not grow efficiently in the lungs of hamsters. BPIV3 strains derived 
from the Kansas/15626/84 strain have been reported to replicate to similar levels in the 
nasal turbinates and the lungs of hamsters (Haller et al., 2000; Schmidt et al., 2001), 
while upper respiratory tract-specific growth of BPIV3 in hamster has been reported 
for the SF-4 strain (Van der Maaten, 1969a). Therefore, it is likely that the differences 
in virus growth in the lungs in our study and in previous studies (Haller et al., 2000; 
Schmidt et al., 2001) may be attributed to the strains used, although our data do not 
exclude the possibility that the EGFP gene introduced in rBPIV3-EGFP may have 
some detrimental effect on virus growth in the lungs. There are 1184 nucleotide (312 
amino acid) differences between the BN-1 and Kansas/15626/84 strains, including a 
24-nucleotide insertion in the non-coding region in the F gene of the BN-1 strain 
(Ohkura et al., 2013). These nucleotide and/or amino acid differences may affect the 
growth of the BPIV3 in the lungs of hamsters. For virus isolation from the lungs, we 
routinely used small pieces of the exterior regions of the lobes, which were far from 
bronchi.  We speculated that sloughed ciliated epithelial cells in the bronchi (Fig. 6) 
were not included in our specimens from the lungs. 
  We observed that luminal ciliated epithelial cells in the nasal turbinates and trachea 
were infected with rBPIV3-EGFP (Fig. 4). This observation is consistent with a 
previous report in which HPIV3 specifically replicated in ciliated cells of in vitro 
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 reconstituted human airway epithelium (Zhang et al., 2005). Cell-cell fusion between 
infected cells and infection of basal cells were not observed in the trachea of hamsters 
(Fig. 4) as previously described (Zhang et al., 2005). We also observed a massive 
shedding of the ciliated cell layer in the bronchi (Fig. 6). Shedding of infected ciliated 
cells have been reported in the in vitro model of human epithelium infected with 
HPIV3 (Zhang et al., 2005). Mucosal epithelial cell shedding in the trachea was also 
reported in BPIV3-infected albino guinea pig (Shi et al., 2014). Thus, if the mucosal 
epithelial cell shedding also occurs in the trachea or bronchi of BPIV3-infected cattle, 
it would increase their susceptibility to secondary bacterial infections including 
Mannheimia haemolytica or Pasteurella multocida, leading to BRDC (Ackermann et 
al., 2000, Griffin et al., 2010).   
  The F protein of BPIV3 BN-1 strain has the preferred furin motif 
(Arg-X-Arg/Lys-Arg) at the F1 and F2 cleavage site, and accordingly, rBPIV3-EGFP 
does not require trypsin for replication in cell culture (Fig. 3). However, EGFP 
expression in tissues and organs other than the respiratory tracts was not observed in 
hamsters.  It is likely that host immunity may restrict BPIV3 replication within the 
respiratory tract (Karron and Collins, 2013).  
  In summary, we investigated the systemic infection and the exact cell tropism of 
BPIV3 in hamsters using EGFP-expressing BPIV3. Our results reveal how infection 
with BPIV3 spreads within the respiratory tract of living animals after intranasal 
inoculation. This model is useful for studying the pathogenicity of BPIV3 and 
BPIV3-associated BRDC. Further studies involving infection of calves, the natural 
 10 
 host, with rBPIV3-EGFP will be needed to confirm the results obtained in this study. 
 
MATERIALS AND METHODS 
Cells and viruses. 
  Madin-Darby bovine kidney (MDBK), Vero, 293, and HeLa monolayer cell cultures 
were maintained in Dulbecco’s modified essential medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS) and antibiotics. HEp-2 and CV-1 monolayer cell 
cultures were maintained in minimal essential medium (MEM) supplemented with 
10% FBS and antibiotics. The BPIV3 BN-1 strain was isolated at the National Institute 
of Animal Health, Japan (Inaba et al., 1963; Ohkura et al., 2013). The modified 
vaccinia virus Ankara (MVA-T7), which expresses the phage T7 RNA polymerase 
(Wyatt et al., 1995), was grown in chicken embryonic fibroblasts.   
 
Cloning of the N, P and L genes of BPIV3 into a pGEM-3 plasmid vector. 
  To construct the N-expressing plasmid, the open reading frame of the N gene was 
synthesized from viral RNA by RT-PCR using the primers 
5’-GCGAATTCATGCTGAGTCTATTTGACAC-3’ and 
5’-GCGAATCCTTAGTTGTTTCCAAATGCAC-3’ and ligated between EcoRI and 
BamHI sites of the pGEM-3 plasmid, resulting in pGEM-N. To construct the 
P-expressing plasmid, the open reading frame of the P gene was synthesized from viral 
RNA by RT-PCR using the primers 
5’-GCTCTAGAATGGAAAACAATGCTAAAGA-3’ and 
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 5’-GCAAGCTTTTACTGAGAGCTGACATCCT-3’ and ligated between XbaI and 
HindIII sites of the pGEM-3 plasmid, resulting in pGEM-P. To construct the 
L-expressing plasmid, the open reading frame of the L gene was synthesized from viral 
RNA by RT-PCR using the primers 
5’-GCGGTACCATGGACACCGAATCCCACAG-3’ and 
5’-GCGCATGCTTAATCAATATCAAATTCGT-3’ and ligated between KpnI and SphI 
of the pGEM-3 plasmid, resulting in pGEM-L. 
 
Construction of the full-length BPIV3 cDNA expressing EGFP. 
  To construct the full-length BPIV3 cDNA, three fragments were amplified from 
viral RNA by RT-PCR and assembled stepwise (Fig. 1). First, the fragment covering 
the BPIV3 leader sequence to the XhoI site at nucleotide position 2154 was amplified 
by RT-PCR. Then a BssHII site and the T7 promoter sequence were added by PCR 
using synthetic primers, resulting in the frg(BssHII-T7-XhoI). Second, the fragment 
covering from the NheI (the StuI site at nucleotide position 7917 was changed to a 
NheI site) to the BPIV3 trailer sequence was amplified, and the genomic hepatitis delta 
virus ribozyme sequence and a NotI site were added by PCR using synthetic primers. A 
XhoI site was added just before the NheI site to join to the frg(BssHII-T7-XhoI), 
resulting in the frg(XhoI-Ribozyme-NotI). Third, the fragment covering from the XhoI 
site at nucleotide position 2154 to the NheI was amplified by RT-PCR, resulting in the 
frg(XhoI-NheI). All fragments were cloned into the pBluescriptII KS(+), whose 
multiple cloning site was replaced with a fragment containing BssHII and NotI sites, 
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 resulting in the p(+)BPIV3. To introduce the EGFP gene between the N and P genes of 
the p(+)BPIV3, an extra gene unit containing a gene-start signal, a gene-end signal, an 
intergenic region, and SalI/MluI sites was inserted between the N and P gene of the 
p(+)BPIV3, resulting in the p(+)BPIV3-S/M. The open reading frame for the EGFP 
gene was amplified from the pEGFP-N1 (Clontech, Mountain View, CA) using the 
primers 5´-TCCTAAGATTGTCGACATGGTGAGCAAGGGCGAG-3´ and 
5´-GATCATCTCTACGCGTCTTACTTGTACAGCTCGTC-3´ (the restriction sites are 
underlined) and introduced between the SalI and MluI sites of the p(+)BPIV3-S/M, 
resulting in the p(+)BPIV3-EGFP. All plasmids containing the full-length BPIV3 
cDNA were prepared in Stbl2 cells (Life technologies, Grand Island, NY) at 30˚C. 
 
Rescue of infectious virus from p(+)BPIV3-EGFP plasmid. 
  HeLa cells in a 6-well plate (80% confluent) were infected with vaccinia virus 
MVA-T7 at a multiplicity of infection (MOI) of 1. One hour postinfection, the 
p(+)BPIV3 or p(+)BPIV3-EGFP plasmids (4 µg) was transfected into the 
MVA-T7-infected HeLa cells together with the pGEM-N, pGEM-P and pGEM-L in the 
presence of 10 µl of lipofectamine 2000 (Life technologies) in 250 µl of Opti-MEM 
(Life technologies). After a 6-hour incubation, media were replaced with DMEM 
supplemented with 10% FBS and antibiotics. Three days post-transfection, the 
supernatants were harvested and transferred onto new MDBK cell monolayers. After 
incubation for 3 days in the presence of 4 µg of 1-β-D-arabinofuranosylcytosine/ml, 
rBPIV3 and rBPIV3-EGFP were recovered from the p(+)BPIV3 and p(+)BPIV3-EGFP, 
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 respectively. 
 
Growth curves. 
Monolayer cultures of MDBK cells in 24-well cluster plates were infected with 
rBPIV3 or rBPIV3-EGFP at an MOI of 0.01 and incubated at 37˚C. At various times, 
media were harvested and the infectious titer was determined by the TCID50 in MDBK 
cells. 
 
Infection of hamsters with BPIV3-EGFP. 
  Five-week-old Syrian golden hamsters (four animals per group) were anesthetized 
with isoflurane and infected intranasally with 1 × 106 TCID50 of rBPIV3-EGFP in a 
100 µl volume. Animals were maintained separately in isolator cages. From 2 up to 8 
days post-infection, animals were euthanized and the nasal turbinates, trachea and 
lungs (approximately 50 mg) were harvested, homogenized, and stored at −80˚C. The 
viral titers in the tissues were determined by TCID50 assay in MDBK cells. All animal 
experiments were performed in compliance with the guidelines of University of 
Tsukuba. 
 
Macroscopic detection of EGFP fluorescence. 
  EGFP fluorescence in the tissues and organs of hamsters was observed using a 
VB-G25 fluorescence microscope equipped with a VB-7000/7010 charge-coupled 
device (CCD) detection system (Keyence, Osaka, Japan) or a BZ-X700 fluorescence 
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 microscope (Keyence) equipped with a cooled CCD digital camera. Composite images 
with a large depth-of-field were created by extracting the pixel information from 
multiple Z-stack images. 
 
Histopathological and immunohistochemical analyses. 
  Tissues from the nasal turbinates and trachea to bronchi were fixed in 10% 
phosphate-buffered formalin.  Fixed tissues were embedded in paraffin, sectioned, 
and stained with hematoxylin and eosin. A portion of the nasal turbinates and trachea 
were also snap-frozen in Tissue-Tek OCT compound (Sakura Finetek, Tokyo, Japan) 
and incubated with a monoclonal antibody against β-tubulin IV (SIGMA, St. Louis, 
MO). Alexa Fluor 568-conjugated donkey anti-mouse IgG (Life technologies) was 
used as the secondary antibody. After a final wash, cells were mounted with 
Vectashield mounting medium (Vector Laboratories, Burlingame, CA), and images 
were acquired using a Keyence BZ-X700 fluorescence microscope equipped with a 
cooled CCD digital camera. 
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FIGURE LEGENDS 
Fig. 1. Construction of antigenomic cDNA of BPIV3 and BPIV3 containing the 
EGFP gene. The BPIV3 genome is flanked by untranslated leader (le) and trailer (tr) 
regions. The boxes between genes indicated the conserved gene-end sequences, 
intergenic sequences (IGS), and gene-start sequences. T7 promoter and Ribozyme are 
located upstream of the leader region (le) and downstream of the trailer region (tr), 
respectively. To construct the full-length BPIV3 cDNA, three fragments, 
frg(BssHII-T7-XhoI), frg(XhoI-Ribozyme-NotI) and frg(XhoI-NheI), were amplified 
from viral RNA by RT-PCR and assembled stepwise, resulting in p(+)BPIV3. An NheI 
restriction enzyme site in the HN gene of p(+)BPIV3 was used as a genetic marker and 
is indicated. The EGFP gene (hatched box) was inserted between the N and P genes. 
The nucleotide sequence between the N and P genes of the p(+)BPIV3 and the 
nucleotide sequences between the N and EGFP and between the EGFP and P genes of 
the p(+)BPIV3-EGFP are indicated.  
 
Fig. 2. Identification of the genetic marker in the recovered rBPIV3 genome. PCR 
fragments, 1020 bp in length, were amplified by RT-PCR from cells infected with 
rBPIV3 or BPIV3. The amplified region contained viral sequences from nt 7680 to 
8700 in the HN gene were digested with NheI or StuI.  The digested and undigested 
PCR fragments were analyzed on a 1% agarose gel.  
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 Fig. 3. Growth of BPIV3, rBPIV3 and rBPIV3-EGFP in MDBK cells and 
dissemination of rBPIV3-EGFP in cultured cell lines. (A) Replication kinetics of 
BPIV3, rBPIV3 and rBPIV3-EGFP.  MDBK cells were infected with BPIV3 (open 
circles), rBPIV3 (filled circles) or rBPIV3-EGFP (triangles) at an MOI of 0.01. Media 
were harvested at days 0, 1, 2, 3, 4, and 5, and infectious titers were assessed as 
TCID50 using MDBK cells. The data presented the mean ± the standard deviations of 
triplicate samples. (B) MDBK, CV-1, Vero, HeLa, HEp-2 and 293 cells were infected 
with rBPIV3-EGFP.  The rBPIV3-EGFP-infected cells were visualized with EGFP 
autofluorescence at day 2 post-infection. Photomicrographs of EGFP fluorescence and 
phase contrast are shown. 
 
Fig. 4. EGFP fluorescence in the upper respiratory tracts of hamsters after 
experimental infection with rBPIV3-EGFP. At day 4 post-infection, rBPIV3-EGFP 
infection in hamsters was detected using a Keyence VB-25 fluorescence microscope. 
The skull of the hamster was cut in sagittal plane (a, b, and c). Photographs were taken 
under daylight (a), ultraviolet light (b and d), or both (c). NT, nasal turbinates; PH, 
pharynx; LA, larynx; TR, trachea. Infection with rBPIV3-EGFP in the trachea was 
detected using a Keyence BZ-X700 fluorescence microscope (e and f). The luminal 
surface of trachea was infected with rBPIV3-EGFP. 
 
Fig. 5. Infection of ciliated cells in the nasal turbinate and trachea by 
rBPIV3-EGFP. The nasal turbinate and trachea obtained from a hamster infected with 
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 rBPIV3-EGFP at day 4 post-infection were investigated by immunofluorescence 
staining. Frozen sections of the nasal turbinate (A) and trachea (B) were observed by 
phase contrast and EGFP expression or stained with antibody against β-tubulin IV. 
DAPI was used to identify nuclei. No cell-to-cell fusion was observed between 
rBPIV3-EGFP-infected cells. 
 
Fig. 6. Bronchi sections from infected hamsters after hematoxylin and eosin 
(H&E) staining. (A) Mucosal ciliated epithelial cell shedding (arrows) and 
lymphocytic infiltration (arrowheads) in the bronchi section of one hamster at day 6 
post-infection. (B) Blood cells and amorphous debris in the bronchial lumen. (C) 
High-magnification image of the boxed area (c) in (A). (D) High-magnification image 
of the boxed area (d) in (B). (E) High-magnification image of the boxed area (e) in (A). 
(F) High-magnification image of another bronchi section of infected hamster. 
Non-ciliated cells (asterisk) induced by mucosal ciliated cell shedding. Bar = 100 µm. 
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Table 1 
Replication of rBPIV3-GFP in the upper and lower respiratory tracts of hamsters 
Days post infection 
Mean virus titer ± SE log10 TCID50/g of tissue) 
Nasal turbinates Trachea 
 
Lungs 
2   6.8 ± 0.2   4.5 ± 0.2  ND 
4 
 
6.7 ± 0.8 
 
5.7 ± 0.5 
 
<3.1 
6 
 
5.7 ± 0.7 
 
3.4 ± 0.8 
 
ND 
8  <3.1  <3.1  ND 
 
ND, not determined. 
 
Table 2 
Replication of rBPIV3 and rBPIV3-EGFP in the upper and lower respiratory tracts of 
hamsters on day 4 post-infection 
Virus 
Mean virus titer ± SE log10 TCID50/g of tissue) 
Nasal turbinates Trachea 
 
Lungs 
rBPIV3   6.2 ± 0.2   5.0 ± 1.0  3.7 ± 1.4 
rBPIV3-EGFP (1×105) ND 
 
6.1 ± 0.4 
 
ND 
rBPIV3-EGFP (1×104) ND  5.5 ± 0.2  ND 
 
ND, not determined. 
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